trending Market Intelligence /marketintelligence/en/news-insights/trending/ypX5j6Zyf9UpdSsIsctd-w2 content esgSubNav
In This List

AeroForm secures US FDA approval for breast-reconstruction device

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


AeroForm secures US FDA approval for breast-reconstruction device

AirXpanders Inc.'s AeroForm system for breast reconstruction was approved by the U.S. FDA.

"The market opportunity for AirXpanders in the U.S. is significant, with the total addressable market worth more than US$800 million. As U.S. mastectomy rates continue to rise and growing numbers of women undergo breast reconstruction, we are confident AeroForm will positively redefine the reconstruction process for women in the U.S.," AirXpanders President and CEO Scott Dodson said in a statement.

The system is targeted for commercial launch in the U.S. in January 2017.